Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. Its lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. The company also markets DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a life-threatening complication of lymphoma, a cancer of the immune system. Its development pipeline comprises DepoMeloxicam, a long-acting non-steroidal anti-inflammatory drug, which is in preclinical development for the treatment of acute postsurgical pain; and DepoTranexamic Acid, a pre-clinical development product for the treatment or prevention of excessive blood loss during surgery by promoting hemostasis. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010.

Parsippany Troy Hills, US
Size (employees)
503 (est)+4%
Pacira Pharmaceuticals was founded in 2006 and is headquartered in Parsippany-Troy Hills, US

Pacira Pharmaceuticals Office Locations

Pacira Pharmaceuticals has offices in Parsippany-Troy Hills, San Diego, New York, Jersey and in 1 other location
Parsippany Troy Hills, US (HQ)
300 5 Sylvan Way
San Diego, US
125 10578 Science Center Dr
San Diego, US
11011 N Torrey Pines Rd

Pacira Pharmaceuticals Metrics

Pacira Pharmaceuticals Financial Metrics

Revenue (2016)

$276.4 m

Revenue growth (2015-16), %


Gross profit

$198.9 m

Gross profit margin (2016), %


Net income (2016)

($37.9 m)

Market capitalization (28-Apr-2017)

$1.8 b

Closing share price (28-Apr-2017)


Cash (31-Dec-2016)

$35.9 m
Pacira Pharmaceuticals's current market capitalization is $1.8 b.
Pacira Pharmaceuticals's revenue was reported to be $276.4 m in FY, 2016 which is a 11% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$85.6 m$197.7 m$249 m$276.4 m

Revenue growth, %


Cost of goods sold

$54.8 m$77.4 m$71.8 m$77.4 m

Gross profit

$30.8 m$120.2 m$177.2 m$198.9 m

Gross profit Margin, %


Operating expense total

$138.8 m$202.8 m$239.5 m$202.8 m


($53.3 m)($5.2 m)$9.5 m($5.2 m)

EBIT margin, %


Interest expense

$7.3 m$8.3 m$7.7 m$8.3 m

Interest income

$259 k$382 k$678 k$382 k

Pre tax profit

($64.4 m)($13.5 m)$2.1 m($13.5 m)

Income tax expense

$442 k($173 k)($264 k)($173 k)

Net Income

($63.9 m)($13.7 m)$1.9 m($37.9 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$12.5 m$37.5 m$57 m$35.9 m

Accounts Receivable

$14.6 m$22.4 m$25.9 m$29.9 m


$15.6 m$29.3 m$6.1 m$9.3 m

Current Assets

$106.8 m$214.3 m$252.6 m$243.1 m


$10.3 m$23.8 m$30.9 m$46.7 m

Total Assets

$169.8 m$326.1 m$389.6 m$391.5 m

Accounts Payable

$3.1 m$6.8 m$8.7 m$7.5 m

Current Liabilities

$121.9 m$140 m$151.7 m$44.8 m

Additional Paid-in Capital

$337.6 m$481.3 m$526.7 m$565.2 m

Retained Earnings

($296.4 m)($310.1 m)($308.3 m)($346.2 m)

Total Equity

$41.2 m$218.4 m$219 m

Financial Leverage

4.1 x1.8 x1.8 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($63.9 m)($13.7 m)$1.9 m($13.7 m)

Depreciation and Amortization

$5.7 m

Accounts Receivable

($10 m)($7.8 m)($3.5 m)($7.8 m)


($3.5 m)($14 m)($32 m)

Accounts Payable

$10.2 m$14.3 m$9.9 m

Cash From Operating Activities

($43.2 m)$25.5 m$29 m$26.6 m

Purchases of PP&E

($12.8 m)

Cash From Investing Activities

($43.6 m)($119.3 m)($20.2 m)($120.4 m)

Long-term Borrowings

($27.5 m)

Cash From Financing Activities

$89.2 m$118.9 m$10.7 m$118.9 m

Income Taxes Paid

$34 k$195 k$34 k

Pacira Pharmaceuticals Market Value History

Pacira Pharmaceuticals Job Categories

Pacira Pharmaceuticals Company Life

You may also be interested in